Apple bids for Formula 1 rights in US, Financial Times reports
(Reuters) -Apple is in talks to acquire the U.S. rights to screen Formula 1 when the broadcast contract becomes available next year, Financial Times reported on Wednesday.
Reuters could not immediately confirm the report.
(Reporting by Anusha Shah in Bengaluru; Editing by Mrigank Dhaniwala)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
a minute ago
- Washington Post
White House creates account on TikTok, the app Trump once tried to ban
The White House launched an account on the popular video app TikTok on Tuesday, sharing a number of videos, including one in which President Donald Trump declares: 'I am your voice.' The U.S. has had a rocky relationship with the Chinese-owned video app across multiple administrations. Federal employees are banned from downloading it on work devices — with limited exceptions — because of concerns that China could collect Americans' user data.
Forbes
a minute ago
- Forbes
Epic's Bold Move: Healthcare's Star Trek Moment With Intelligent AI Agents
Epic, long a dominant force in electronic medical records (EMR), has just taken a leap into the future of healthcare AI. This week, CEO Judy Faulkner announced that Epic is moving beyond traditional artificial intelligence, coining the term 'healthcare intelligence' to describe its new approach: developing intelligent AI agents within its EMR to transform the entire healthcare ecosystem. The move is a bold, strategic play—one that brings the visionary technologies of Star Trek into real-world patient care. At the core of this AI transformation is Epic's Cosmos dataset, encompassing over 300 million patient records and more than 16 billion encounters across four countries—a formidable advantage that sets Epic apart from its competitors. Epic's new AI agents are at the heart of this transformation: • Emmie, the patient-facing advocate, acts as a personal navigator for care—scheduling, reminders, education, and MyChart-based clinical guidance. She functions like Star Trek's Universal Translator, breaking down language and literacy barriers while delivering personalized guidance. • ART, the clinician copilot, extends AI scribing, pre-visit summaries, order suggestions, and real-time evidence-based guidance. ART embodies the Ship's Computer, allowing clinicians to ask complex questions naturally and receive actionable, context-aware answers in real time. • Cosmos AI, powered by Epic's enormous dataset, supports diagnosis, treatment planning, and predictive analytics at scale. It is the Medical Tricorder, instantly synthesizing labs, imaging, notes, and genomics to propose care pathways and support clinical decision-making. • Penny, the administrative optimizer, tackles prior authorization, revenue capture, and operational bottlenecks. She mirrors the Holodeck EMH, acting as an autonomous support system that extends both clinical and operational capacity, especially in high-demand or underserved settings. Beyond these agents, Epic is embedding Predictive Health Monitoring, mirroring the Star Trek sensors that detect physiological changes before symptoms appear. AI-driven models now identify risk for deterioration, sepsis, readmissions, and other complications, enabling proactive intervention. Epic's strategy raises key questions for the broader healthcare ecosystem: • How will these AI agents integrate with smaller health systems, which historically relied on lighter EHR solutions or Community Connect models? Can pooled resources and nimble implementations allow these systems to adopt Epic without prohibitive costs? • What role will payers play as AI-driven predictive models inform coverage decisions, pre-authorization, and risk stratification? Could these tools reshape payer-provider negotiations or accelerate value-based care adoption? Could this ultimately address payers' long-standing transparency challenges with claims data? • How will pharmacies leverage ART and Cosmos AI for medication management, adherence monitoring, and personalized therapy recommendations? • Can clinical trial enrollment be streamlined through AI-guided matching, making research more accessible and inclusive for patients across diverse settings? • Governance: How will health systems ensure safe, ethical, and compliant use of AI agents across clinical and operational workflows? Who sets the standards, monitors performance, and maintains accountability when agentic AI decisions influence patient care or challenge provider decisions? Strategically, Epic is partnering deeply with Microsoft, leveraging Azure AI to power its AI scribing capabilities. This ensures scale, reliability, and long-term alignment while preventing fragmentation from third-party solutions. ART, Emmie, Cosmos AI, and Penny together create a unified, interoperable ecosystem—one that consolidates Epic's market power, enhances operational efficiency, and raises the bar for competitors. For patients, the benefits are immediate: a single sign-on for MyChart across all sites, AI-powered wound assessments, integrated clinical trial enrollment, and personalized guidance across the entire care journey. For clinicians, the EMR becomes a co-pilot rather than a cumbersome tool, guiding decision-making, reducing administrative burden, and supporting evidence-based care. Final Perspective Epic's AI strategy represents a healthcare Star Trek moment: intelligent, agentic systems that empower human operators, anticipate problems before they occur, and extend care capabilities across every layer of the ecosystem. It is not just about technology—it's a bold vision for a fully connected, intelligent healthcare universe where hospitals, payers, pharmacies, and patients interact seamlessly, and the future of care becomes more predictive, efficient, and patient-centric.
Yahoo
29 minutes ago
- Yahoo
Keysight Technologies Inc (KEYS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and AI ...
This article first appeared on GuruFocus. Revenue: $1.4 billion, up 11% year-over-year. Earnings Per Share (EPS): $1.72, exceeding guidance. Orders: Increased by 7% year-over-year. Gross Margin: 64%. Operating Expenses: $526 million. Operating Margin: 25%, up 60 basis points from last year. Net Income: $297 million. Communications Solutions Group Revenue: $940 million, up 11% year-over-year. Electronic Industrial Solutions Group Revenue: $412 million, up 11% year-over-year. Cash Flow from Operations: $322 million. Free Cash Flow: $291 million. Cash and Cash Equivalents: $2.636 billion. Share Repurchase: 300,000 shares at an average price of $164, totaling $50 million. Q4 Revenue Guidance: $1.370 billion to $1.390 billion. Q4 EPS Guidance: $1.79 to $1.85. Warning! GuruFocus has detected 6 Warning Signs with VVOS. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Keysight Technologies Inc (NYSE:KEYS) reported an 11% year-over-year increase in revenue to $1.4 billion, exceeding the high end of their guidance. Orders increased by 7% with growth across both the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The company saw strong growth in aerospace, defense, government, and general electronics, with stability in wireless and automotive sectors. Keysight Technologies Inc (NYSE:KEYS) is capitalizing on AI momentum, with significant investments in AI-related technologies and partnerships, such as with AMD for PCIe Gen 6 compliance validation. The company reported a gross margin of 64% and an operating margin of 25%, with earnings per share of $1.72, up 9% year over year. Negative Points The company is facing challenges with tariffs, which are expected to increase their tariff exposure by approximately $75 million annually. Despite strong performance, the automotive sector remains stable year over year, indicating potential challenges in achieving growth in this segment. The broader 6G commercialization is still years away, which may delay potential revenue from this technology. The company is experiencing headwinds in the semiconductor sector, despite robust demand for wafer test solutions. There are ongoing geopolitical and macroeconomic uncertainties that could impact future performance and market conditions. Q & A Highlights Q: Satish, on past calls, you characterized your expectation for a recovery in the end markets overall as gradual. I don't think I heard you use that word today. Can you help investors understand your view of the end markets now and to what extent it's better than you'd previously expected? A: Strong quarter, clearly, and we're feeling good about the funnel and customer activity despite the overhang from tariffs and geopolitical environment. Order growth has accelerated, and we're feeling slightly better than expected at the beginning of the year. However, not all end markets are up; AI and aerospace defense are strong, while automotive faces challenges. Q: Can you help us better understand what's supporting the revenue outlook into 4Q, given that orders were up high-single digits but the book-to-bill was just below 1? A: Some of this is due to the timing of big deals. We had a large system integration deal accepted on the last day of Q3, which elevated Q3 performance and pulled from Q4. We expect more normal sequential seasonality on the order front than on the revenue front due to the timing of these deals. Q: Neil, as we think about revenue growth and recovery, you mentioned a 5% to 7% top-line growth rate as a long-term model. Is that how we should think about fiscal '26? A: We started the year with a gradual recovery expectation and are now looking at revenue growth at the low end of that range. Things have unfolded slightly better, allowing us to raise expectations. We're bullish going into '26, with caution around tariffs and macroeconomic factors. Q: How do you respond to investors asking about the mix of AI's contribution to the Keysight story, particularly in wireline? A: We're well-positioned for the long-term AI opportunity. AI will contribute across multiple end markets over time. Wireline business is expected to finish strong due to AI demand. It's hard to isolate AI's impact as it involves entrenched ecosystems, but business with us is growing, driven by AI. Q: Can you outline where the tariffs are most substantial for you, and is the mitigation plan focused on moving production or pricing? A: We have a geographically diverse manufacturing footprint, with significant operations in Southeast Asia, the EU, Japan, and the US. Mitigation involves supply chain strategies, possibly shifting manufacturing, and passing costs to customers through price increases and surcharges. We expect to fully mitigate the April tariffs by Q1 and the August increase by the first half of FY26. Q: On aerospace and defense, should we see this market continue to accelerate, or is this a good level due to the time it takes for programs to get into place? A: The starting point for the year was slower, but demand has returned in the second half. Ongoing programs and backlog for prime contractors are robust, indicating a positive environment. The US situation is understood, and European spending could impact long-term growth. Aerospace and defense are steady value creators, though growth may not be as quick as commercial markets. Q: Could you touch on the moving parts around the incremental margin of 40% you talked about? A: The 40% incremental margin is the right long-term target. Tariffs impacted this year's ability to deliver, but once included in the baseline, we can achieve it with mid-single-digit growth. Stripping out tariff impact, we are overachieving the 40% incremental in recent quarters. Q: Can you provide thoughts on customer engagement timelines and when 6G might become a more meaningful revenue contributor? A: Recent 3GPP meetings reinforced industry alignment from 5G to 6G, which is positive for us. Customers are exploring 6G facets, building IP for eventual rollout. While years away from rollout, R&D activity will grow, and we're well-positioned to support this transition. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
